Communiqués Arcellx, Inc.

Actions

ACLX

US03940C1009

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 27/04/2026			Varia. 5j.	Varia. 1 janv.
115,07 ^USD	+0,03%		-.--%	+76,49%

07/05	Gilead relève ses prévisions de ventes pour 2026 mais anticipe un impact sur ses résultats dû aux acquisitions	RE
28/04	Arcellx, Inc. annonce des changements au sein de son conseil d'administration	CI

Communiqués

13/03	Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc. - ACLX	BU
24/02	Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc. - ACLX	BU
23/02	Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel	BU
04/02	Arcellx Announces Late-Breaking Presentation at TANDEM Demonstrating Unique, High Target-Specificity of anito-cel’s D-Domain Binder	BU
21/01	Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem Meetings	BU
06/12	Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma	BU
18/11	Arcellx to Host Investor Relations Event During the 67th ASH Annual Meeting and Exposition	BU
05/11	Arcellx Provides Third Quarter 2025 Financial Results	BU
03/11	Arcellx to Present New Data for Its iMMagine-1 Study and Continues Scientific Momentum with Multiple Presentations at the 67th ASH Annual Meeting and Exposition	BU
03/09/25	Arcellx to Participate at the 2025 Morgan Stanley Global Healthcare Conference	BU
07/08/25	Arcellx Provides Second Quarter 2025 Financial Results and Business Highlights	BU
21/05/25	Arcellx Announces Its Participation at TD Cowen’s 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025	BU
14/05/25	Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma	BU
08/05/25	Arcellx Provides First Quarter 2025 Financial Results and Business Highlights	BU
20/03/25	Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors	BU
27/02/25	Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights	BU
26/02/25	Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference	BU
09/12/24	Arcellx : Announces New Positive Data for its iMMagine 1 Study in Patients with Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition Form 8 K	PU
09/12/24	Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition	BU
08/11/24	Arcellx : Provides Third Quarter 2024 Financial Results and Business Highlights Form 8 K	PU
08/11/24	Arcellx : Quarterly Report for Quarter Ending September 30, 2024 (Form 10-Q)	PU
07/11/24	Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights	BU
05/11/24	Arcellx : to Present Clinical Data for Its Phase 1 and iMMagine 1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine 3 Study Form 8 K	PU
05/11/24	Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study	BU
02/10/24	Arcellx : October 2024 Corporate Presentation	PU